We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Shares of the U.K. drugmaker careened to $1.44 per share in late trading Wednesday on the heels of a Bloomberg report that Mallinckrodt hired two firms to walk through bankruptcy options as a federal opioid lawsuit roundup approaches trial next month.